Notice Information
Notice Title
Provision of Sequencing Panel for Detection of Gene Fusions In Cancer
Notice Description
The All Wales Genomics Laboratory intends to procure an RNA sequencing panel to enable the identification of gene fusion events in somatic tissue samples, to replace the current laboratory tests. AWGL currently offers a range of gene fusion detection services using predominantly fluorescence in situ hybridisation (FISH) together with a limited number of qPCR assays. These tests cover the common genetic translocations seen in haematological malignancies, lymphomas, sarcomas and solid tumour referrals in a range of tissues including bone marrow, peripheral blood and formalin-fixed paraffin embedded (FFPE) tissues.
Lot Information
Lot 1
The All Wales Genomics Laboratory intends to procure an RNA sequencing panel to enable the identification of gene fusion events in somatic tissue samples. AWGL currently offers a range of gene fusion detection services using predominantly fluorescence in situ hybridisation (FISH) together with a limited number of qPCR assays. These tests cover the common genetic translocations seen in haematological malignancies, lymphomas, sarcomas and solid tumour referrals in a range of tissues including bone marrow, peripheral blood and formalin-fixed paraffin embedded (FFPE) tissues. In 2020/21 the laboratory received referrals from over 3000 samples for gene fusion translocation testing. Many of these samples were interrogated for more than 1 gene fusion event. The laboratory intends to introduce and NGS assay that will ensure the following objectives are met- - Workflow Standardisation - Introduction of a single NGS assay that can be used to detect a variety of clinically relevant gene fusions, across a range of sample types and cancers. - Streamlining Analysis - NGS assay allows the transfer of fusion analysis from predominantly microscopy based analyses (FISH) to a more sensitive and standardised method. - Service Improvement - Allows reduction of turnaround times by simultaneous detection of all clinically relevant gene fusion events using a protocol that is amenable to automation. - Expansion of gene fusion testing repertoire - Flexibility in panel content for future proofing against new testing requirements in cancer. We anticipate that an invitation to tender will be published in autumn 2021, with a view to begin service delivery in spring 2022. AWGL invite suppliers to present their solution via Teams/Skype/Zoom on a mutually convenient time/date between Monday 5th July and Friday 16th July 2021. The presentation should detail how your solution may best meet our needs with time for questions at the end. Please contact Ryan James, ryan.james3@wales.nhs.uk to arrange a meeting, where you will be provided a list of information that the laboratory requests you cover in your presentation.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-02b8e4
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/012659-2021
- Current Stage
- Planning
- All Stages
- Planning
Procurement Classification
- Notice Type
- Planning Notice
- Procurement Type
- Standard
- Procurement Category
- Goods
- Procurement Method
- Not Specified
- Procurement Method Details
- Not specified
- Tender Suitability
- Not specified
- Awardee Scale
- Not specified
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33696500 - Laboratory reagents
Notice Value(s)
- Tender Value
- Not specified
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- Not specified
Notice Dates
- Publication Date
- 7 Jun 20214 years ago
- Submission Deadline
- Not specified
- Future Notice Date
- 30 Sep 2021Expired
- Award Date
- Not specified
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Planned
- Lots Status
- Planned
- Awards Status
- Not Specified
- Contracts Status
- Not Specified
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS WALES SHARED SERVICES PARTNERSHIP-PROCUREMENT SERVICES (HOSTED BY VELINDRE UNIVERSITY NHS TRUST)
- Contact Name
- Ryan James
- Contact Email
- ryan.james3@wales.nhs.uk
- Contact Phone
- +44 2921836442
Buyer Location
- Locality
- CARDIFF
- Postcode
- CF15 7QZ
- Post Town
- Cardiff
- Country
- Wales
-
- Major Region (ITL 1)
- TLL Wales
- Basic Region (ITL 2)
- TLL5 South East Wales
- Small Region (ITL 3)
- TLL51 Central Valleys and Bridgend
- Delivery Location
- TLL22 Cardiff and Vale of Glamorgan
-
- Local Authority
- Rhondda Cynon Taf
- Electoral Ward
- Taff's Well
- Westminster Constituency
- Cardiff North
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-02b8e4-2021-06-07T12:15:03+01:00",
"date": "2021-06-07T12:15:03+01:00",
"ocid": "ocds-h6vhtk-02b8e4",
"description": "NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=111195. (WA Ref:111195)",
"initiationType": "tender",
"tender": {
"id": "ocds-h6vhtk-02b8e4",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "Provision of Sequencing Panel for Detection of Gene Fusions In Cancer",
"status": "planned",
"classification": {
"scheme": "CPV",
"id": "33696500",
"description": "Laboratory reagents"
},
"mainProcurementCategory": "goods",
"description": "The All Wales Genomics Laboratory intends to procure an RNA sequencing panel to enable the identification of gene fusion events in somatic tissue samples, to replace the current laboratory tests. AWGL currently offers a range of gene fusion detection services using predominantly fluorescence in situ hybridisation (FISH) together with a limited number of qPCR assays. These tests cover the common genetic translocations seen in haematological malignancies, lymphomas, sarcomas and solid tumour referrals in a range of tissues including bone marrow, peripheral blood and formalin-fixed paraffin embedded (FFPE) tissues.",
"lots": [
{
"id": "1",
"description": "The All Wales Genomics Laboratory intends to procure an RNA sequencing panel to enable the identification of gene fusion events in somatic tissue samples. AWGL currently offers a range of gene fusion detection services using predominantly fluorescence in situ hybridisation (FISH) together with a limited number of qPCR assays. These tests cover the common genetic translocations seen in haematological malignancies, lymphomas, sarcomas and solid tumour referrals in a range of tissues including bone marrow, peripheral blood and formalin-fixed paraffin embedded (FFPE) tissues. In 2020/21 the laboratory received referrals from over 3000 samples for gene fusion translocation testing. Many of these samples were interrogated for more than 1 gene fusion event. The laboratory intends to introduce and NGS assay that will ensure the following objectives are met- - Workflow Standardisation - Introduction of a single NGS assay that can be used to detect a variety of clinically relevant gene fusions, across a range of sample types and cancers. - Streamlining Analysis - NGS assay allows the transfer of fusion analysis from predominantly microscopy based analyses (FISH) to a more sensitive and standardised method. - Service Improvement - Allows reduction of turnaround times by simultaneous detection of all clinically relevant gene fusion events using a protocol that is amenable to automation. - Expansion of gene fusion testing repertoire - Flexibility in panel content for future proofing against new testing requirements in cancer. We anticipate that an invitation to tender will be published in autumn 2021, with a view to begin service delivery in spring 2022. AWGL invite suppliers to present their solution via Teams/Skype/Zoom on a mutually convenient time/date between Monday 5th July and Friday 16th July 2021. The presentation should detail how your solution may best meet our needs with time for questions at the end. Please contact Ryan James, ryan.james3@wales.nhs.uk to arrange a meeting, where you will be provided a list of information that the laboratory requests you cover in your presentation.",
"status": "planned"
}
],
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33696500",
"description": "Laboratory reagents"
}
],
"deliveryAddresses": [
{
"region": "UKL22"
}
],
"deliveryLocation": {
"description": "All Wales Genomics Laboratory Institute of Medical Genetics University Hospital of Wales Heath Park Cardiff CF14 4XW"
},
"relatedLot": "1"
}
],
"communication": {
"futureNoticeDate": "2021-10-01T00:00:00+01:00"
},
"coveredBy": [
"GPA"
]
},
"parties": [
{
"id": "GB-FTS-109",
"name": "NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)",
"identifier": {
"legalName": "NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)"
},
"address": {
"streetAddress": "4-5 Charnwood Court,, Heol Billingsley, Parc Nantgarw",
"locality": "Cardiff",
"region": "UK",
"postalCode": "CF15 7QZ",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Ryan James",
"telephone": "+44 2921836442",
"email": "ryan.james3@wales.nhs.uk"
},
"roles": [
"buyer",
"centralPurchasingBody"
],
"details": {
"url": "http://nwssp.nhs.wales/ourservices/procurement-services/",
"buyerProfile": "https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
}
],
"buyer": {
"id": "GB-FTS-109",
"name": "NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)"
},
"language": "en"
}